AEZS | Aeterna Zentaris Inc
Category: Consumer goods
Quick infos Trade prices Volume: Market Cap: 26.23M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: May 10, 2023
Earnings History Date EPS / Forecast Revenue / Forecast May 10, 2023 March 23, 2023 -2.56 / -0.932.5M / 1.06MBeat! November 3, 2022 -0.7 / -0.681.86M / 4MBeat! August 3, 2022 -0.87 / -0.68-222K / 1.31MMay 11, 2022 -0.5 / -0.021.5M / 740Kview more
Historical Data Date Price Open High Low Vol Change ER Aug 10, 2022 6.550 6.180 6.670
6.180
2.92K 2.99% Aug 9, 2022 6.360 6.400 6.400
6.360
0.50K 0.32% Aug 8, 2022 6.340 6.260 6.340
6.240
0.31K -0.63% Aug 5, 2022 6.380 6.100 6.415
6.100
4.24K 3.40% Aug 4, 2022 6.170 6.480 7.400
5.980
21.65K -2.6% Aug 3, 2022 6.335 5.950 7.000
5.900
10.75K 7.01% Aug 2, 2022 5.920 5.740 5.920
5.740
3.67K 4.04% Jul 29, 2022 5.690 5.730 5.730
5.540
3.99K -0.35% Jul 28, 2022 5.710 5.610 5.990
5.610
3.01K -0.35% Jul 27, 2022 5.730 5.530 5.730
5.500
2.85K 3.06% view more
News
Aeterna Zentaris GAAP EPS of -$0.70 misses by $0.02, revenue of $1.9M beats by $0.57M seekingalpha.com Nov 3, 2022 9:02 pm Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk seekingalpha.com Aug 29, 2022 10:12 pm Aeterna Zentaris GAAP EPS of -$0.87, revenue of $0.2M seekingalpha.com Aug 4, 2022 5:45 am Aeterna slips ~10% after announcing date of reverse stock split seekingalpha.com Jul 19, 2022 9:51 pm Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe seekingalpha.com May 25, 2022 8:57 pm
Aeterna Zentaris: 1Q Earnings Snapshot finance.yahoo.com Aug 11, 2020 6:22 pm
Aeterna Zentaris Reports Third Quarter 2018 Financial and Operating Results finance.yahoo.com Aug 11, 2020 6:14 pm
Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results finance.yahoo.com Aug 11, 2020 4:15 pm Aeterna Zentaris GAAP EPS of -$0.02, revenue of $1.5M seekingalpha.com May 11, 2022 8:13 pm Aeterna Zentaris gets European patent related to macimorelin to detect growth hormone deficiency seekingalpha.com Apr 19, 2022 9:24 pm Aeterna Zentaris GAAP EPS of -$0.02 in-line, revenue of $1M beats by $0.37M seekingalpha.com Mar 29, 2022 8:47 pm Aeterna Zentaris pivotal growth hormone deficiency trial sees recruitment delays seekingalpha.com Mar 21, 2022 9:11 pm Aeterna Zentaris expands research program for COVID-19/Chlamydia vaccines seekingalpha.com Mar 10, 2022 9:33 pm Aeterna Zentaris to get US patent for potential hormone disorder therapy AEZS-150 seekingalpha.com Mar 2, 2022 10:42 pm Aeterna Zentaris gets 180-day extension to comply with Nasdaq's minimum bid price rule seekingalpha.com Jan 27, 2022 5:18 am Aeterna Zentaris provides pipeline updates seekingalpha.com Jan 27, 2022 12:51 am Aeterna Zentaris names new finance chief seekingalpha.com Dec 24, 2021 5:19 am Aeterna Zentaris revenue in-line seekingalpha.com Nov 5, 2021 5:24 am Aeterna Zentaris receives Nasdaq notice for non-compliance with minimum bid price seekingalpha.com Jul 29, 2021 8:27 pm Aeterna Zentaris starts preclinical development of macimorelin in amyotrophic lateral sclerosis seekingalpha.com May 17, 2021 9:00 pm Talk about Aeterna Zentaris Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.